MedinCell S.A.
MDCLF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $26 | $9 | $10 | $4 |
| % Growth | 178.8% | -7.9% | 143.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $26 | $9 | $10 | $4 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $24 | $21 | $28 | $24 |
| G&A Expenses | $0 | $9 | $7 | $6 |
| SG&A Expenses | $1 | $12 | $10 | $8 |
| Sales & Mktg Exp. | $1 | $3 | $3 | $2 |
| Other Operating Expenses | $12 | -$2 | $0 | $0 |
| Operating Expenses | $36 | $30 | $34 | $28 |
| Operating Income | -$11 | -$21 | -$24 | -$24 |
| % Margin | -42.4% | -229% | -241.6% | -582.2% |
| Other Income/Exp. Net | -$7 | -$4 | -$8 | -$1 |
| Pre-Tax Income | -$18 | -$25 | -$32 | -$25 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18 | -$25 | -$32 | -$25 |
| % Margin | -72.2% | -273.3% | -321.9% | -606.5% |
| EPS | -0.63 | -0.88 | -1.27 | -1 |
| % Growth | 28.4% | 30.7% | -27% | – |
| EPS Diluted | -0.63 | -0.88 | -1.27 | -1 |
| Weighted Avg Shares Out | 29 | 28 | 25 | 25 |
| Weighted Avg Shares Out Dil | 29 | 28 | 25 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | -$0 | $0 | $0 |
| Interest Expense | $5 | $5 | $4 | $2 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$11 | -$19 | -$26 | -$21 |
| % Margin | -43.9% | -203.2% | -265.6% | -524.4% |